Indeed, the lack of overlap between the transcriptional consequences of mutations in different splicing factors may explain why they have such profoundly different clinical phenotypes, with SF3B1 mutations driving a benign MDS associated with ring sideroblasts and SRSF2 mutations driving a more aggressive myelomonocytic disease. The gene discussed is SRSF2; the disease is myelodysplastic syndrome.